Kidney outcomes for children with lupus nephritis.

Abstract

Systemic lupus erythematosus is a rare lifelong multi-systemic autoimmune condition. Juvenile-onset SLE (JSLE) is recognized to have a more active disease course when compared with adult-onset disease and patients have a worse long-term survival. Kidney involvement occurs in over 50% of children and treatment decisions are guided by the histological classification. Several international groups have produced treatment protocols that rely on an intense period of immunosuppression to halt the acute kidney inflammatory process, followed by maintenance therapy with close observation for disease improvement and prompt evaluation of disease flares. A reduced glomerular filtration rate at presentation is predictive of later stage chronic kidney disease (CKD) in multivariate analysis. Kidney remission remains suboptimal with only 40-60% of patients achieving complete remission. Kidney flares are seen in over a third of patients. The rate of CKD 5 is reported to be up to 15% and the presence of lupus nephritis (LN) has an established link with an associated increase in mortality. In established kidney failure, transplantation seems to be the optimal kidney replacement modality for this group of patients, ideally after a period of disease quiescence. Modified outcome measures in clinical trials have demonstrated that biologic agents can be effective in this disease. Current biologic agents under investigation include obinutuzimab, belimumab, atacicept, anifrolumab, tocilizumab, eculizumab, dapirolizumab, and abatacept. Future research should focus on discovering early disease biomarkers, including surrogates for later cardiovascular disease, and evaluating biological agents as adjuncts to improve the rates of complete remission and subsequently influence the kidney outcome. The aim of this review article is to summarize the current kidney outcomes for this disease with a view to identifying key areas that may help to reduce the risk of long-term CKD.

• Authors: Louise Oni, Rachael D Wright, Stephen Marks, Michael W Beresford, Kjell Tullus
• Journal: Pediatric nephrology (Berlin, Germany) (Pediatr Nephrol) Vol. 36 Issue 6 Pg. 1377-1385 (06 2021) ISSN: 1432-198X [Electronic] Germany
• PMID: 32725543 (Publication Type: Journal Article, Review)

Chemical References

• Biological Factors

Topics

• Biological Factors
• Humans
• Kidney (physiopathology)
• Lupus Erythematosus, Systemic
• Lupus Nephritis (complications, drug therapy)
• Renal Insufficiency, Chronic (therapy)